Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

BOTHELL, Wash., Sept. 03, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that Company management will participate in the Cantor Global Healthcare Conference 2026, taking place September 9-11, 2026 in New York, NY.

On Track to Complete Enrollment of Phase 3 ELAINE-3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline Data Expected in 2H 2027

BOTHELL, Wash., Aug. 12, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that its lead product candidate, lasofoxifene, will be featured in multiple presentations at Dava Oncology's 4th Summit on Breast Cancer taking place from August 18-22, 2026, in Kona, Hawaii.